174 related articles for article (PubMed ID: 3889175)
1. Cross-reactive immunoprotective antibodies to Escherichia coli O111 rough mutant J5.
Sakulramrung R; Domingue GJ
J Infect Dis; 1985 Jun; 151(6):995-1004. PubMed ID: 3889175
[TBL] [Abstract][Full Text] [Related]
2. Antibody specific for Escherichia coli J5 cross-reacts to various degrees with an Escherichia coli clinical isolate grown for different lengths of time.
McCallus DE; Norcross NL
Infect Immun; 1987 May; 55(5):1042-6. PubMed ID: 3552983
[TBL] [Abstract][Full Text] [Related]
3. Antigenic homology of endotoxin with a coliform mastitis vaccine strain, Escherichia coli O111:B4 (J5).
Tyler JW; Spears H; Nelson R
J Dairy Sci; 1992 Jul; 75(7):1821-5. PubMed ID: 1500577
[TBL] [Abstract][Full Text] [Related]
4. Use of mucin and hemoglobin in experimental murine gram-negative bacteremia enhances the immunoprotective action of antibodies reactive with the lipopolysaccharide core region.
Appelmelk BJ; Verwey-van Vught AM; Maaskant JJ; Schouten WF; Thijs LG; Maclaren DM
Antonie Van Leeuwenhoek; 1986; 52(6):537-42. PubMed ID: 3545072
[TBL] [Abstract][Full Text] [Related]
5. Induction of immunity against lethal Haemophilus influenzae type b infection by Escherichia coli core lipopolysaccharide.
Marks MI; Ziegler EJ; Douglas H; Corbeil LB; Braude AI
J Clin Invest; 1982 Apr; 69(4):742-9. PubMed ID: 7042755
[TBL] [Abstract][Full Text] [Related]
6. Failure of antisera to J5 and R595 rough mutants to reduce endotoxemic lethality.
Greisman SE; Johnston CA
J Infect Dis; 1988 Jan; 157(1):54-64. PubMed ID: 2447200
[TBL] [Abstract][Full Text] [Related]
7. Antiserum against Escherichia coli J5: a re-evaluation of its in vitro and in vivo activity against heterologous gram-negative bacteria.
Trautmann M; Hahn H
Infection; 1985; 13(3):140-5. PubMed ID: 3897069
[TBL] [Abstract][Full Text] [Related]
8. Demonstration of cross-reactive antibodies to smooth gram-negative bacteria in antiserum to Escherichia coli J5.
Baumgartner JD; O'Brien TX; Kirkland TN; Glauser MP; Ziegler EJ
J Infect Dis; 1987 Jul; 156(1):136-43. PubMed ID: 2439613
[TBL] [Abstract][Full Text] [Related]
9. Antigenic and immunogenic characteristics of subcellular fractions and whole cells of a rough E. coli 0111 (J5) mutant.
Sakulramrung R; Domingue GJ
Immunobiology; 1985 May; 169(4):372-88. PubMed ID: 2408995
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of gram-negative bacterial sepsis: enhanced survival in a guinea pig model by use of rabbit antiserum to Escherichia coli J5.
Dunn DL; Ferguson RM
Surgery; 1982 Aug; 92(2):212-9. PubMed ID: 7048594
[TBL] [Abstract][Full Text] [Related]
11. Protective effects of murine monoclonal antibodies in experimental septicemia: E. coli antibodies protect against different serotypes of E. coli.
Salles MF; Mandine E; Zalisz R; Guenounou M; Smets P
J Infect Dis; 1989 Apr; 159(4):641-7. PubMed ID: 2647860
[TBL] [Abstract][Full Text] [Related]
12. Characterization of murine monoclonal antibodies to Escherichia coli J5.
Miner KM; Manyak CL; Williams E; Jackson J; Jewell M; Gammon MT; Ehrenfreund C; Hayes E; Callahan LT; Zweerink H
Infect Immun; 1986 Apr; 52(1):56-62. PubMed ID: 3514463
[TBL] [Abstract][Full Text] [Related]
13. Cross-reactive antibody in immunity to colisepticemia in calves.
Wickstrom ML; Gay CC; Hodgson JL; Widders PR; Schaeffer D; Lee R; Corbeil LB
Vet Microbiol; 1987 Mar; 13(3):259-71. PubMed ID: 3310376
[TBL] [Abstract][Full Text] [Related]
14. Antibodies to lipopolysaccharides after immunization of humans with the rough mutant Escherichia coli J5.
Baumgartner JD; Heumann D; Calandra T; Glauser MP
J Infect Dis; 1991 Apr; 163(4):769-72. PubMed ID: 2010630
[TBL] [Abstract][Full Text] [Related]
15. A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis Group B outer membrane protein produces protective antibodies against gram-negative bacteremia.
Bhattacharjee AK; Opal SM; Taylor R; Naso R; Semenuk M; Zollinger WD; Moran EE; Young L; Hammack C; Sadoff JC; Cross AS
J Infect Dis; 1996 May; 173(5):1157-63. PubMed ID: 8627067
[TBL] [Abstract][Full Text] [Related]
16. Carumonam enhances reactivity of Escherichia coli with mono- and polyclonal antisera to rough Escherichia coli J5.
Overbeek BP; Schellekens JF; Lippe W; Dekker BA; Verhoef J
J Clin Microbiol; 1987 Jun; 25(6):1009-13. PubMed ID: 2439534
[TBL] [Abstract][Full Text] [Related]
17. Protective capacity of antibodies to outer-membrane components of Escherichia coli in a systemic mouse peritonitis model.
Vuopio-Varkila J; Karvonen M; Saxén H
J Med Microbiol; 1988 Feb; 25(2):77-84. PubMed ID: 2448461
[TBL] [Abstract][Full Text] [Related]
18. Antigenic and immunogenic differences in lipopolysaccharides of Escherichia coli J5 vaccine strains of different origins.
Appelmelk BJ; Maaskant JJ; Verweij-van Vught AM; van der Meer NM; Thijs BG; MacLaren DM
J Gen Microbiol; 1993 Nov; 139(11):2641-7. PubMed ID: 7506295
[TBL] [Abstract][Full Text] [Related]
19. Immunochemical specificity of human antibodies to lipopolysaccharide from the J5 rough mutant of Escherichia coli O111:B4.
Schwartzer TA; Alcid DV; Numsuwan V; Gocke DJ
J Infect Dis; 1989 Jan; 159(1):35-42. PubMed ID: 2462603
[TBL] [Abstract][Full Text] [Related]
20. Shielding Effect of Escherichia coli O-Antigen Polysaccharide on J5-Induced Cross-Reactive Antibodies.
Rainard P; Repérant-Ferter M; Gitton C; Germon P
mSphere; 2021 Jan; 6(1):. PubMed ID: 33504665
[No Abstract] [Full Text] [Related]
[Next] [New Search]
